GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Financiere de Tubize SA (XBRU:TUB) » Definitions » Short Interest

Financiere de Tubize (XBRU:TUB) Short Interest


View and export this data going back to 1985. Start your Free Trial

What is Financiere de Tubize Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Financiere de Tubize's Short Interest

For the Biotechnology subindustry, Financiere de Tubize's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Financiere de Tubize's Short Interest Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Financiere de Tubize's Short Interest distribution charts can be found below:

* The bar in red indicates where Financiere de Tubize's Short Interest falls into.


Financiere de Tubize (XBRU:TUB) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Financiere de Tubize SA (XBRU:TUB) » Definitions » Short Interest
Comparable Companies
XBRU:HYL XBRU:ONWD XBRU:ALIMG XBRU:CYAD XBRU:BIOS XBRU:OXUR XBRU:ARGX OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB BNTX OCSE:GMAB ALNY BGNE BMRN
Traded in Other Exchanges
FTD:Germany
Address
Allée de la Recherche, 60, Brussels, BEL, 1070
Website
https://www.financiere-tubize.be
Financiere de Tubize SA is a holding company that owns a stake in UCB, a biopharmaceutical company. UCB is a global biotechnology company that develops treatments for conditions related to neurology and immunology. UCB generates the vast majority of its revenue in the United States, followed by Europe and other international markets. Most of its sales revenue is derived from its neurology products, followed by its immunology products. The company's strategy focuses on leveraging scientific advances and skills in areas such as genetics, biomarkers, and human biology.

Financiere de Tubize (XBRU:TUB) Headlines

No Headlines